Home
Industry Reports
Pharmaceuticals and Healthcare

Pharmaceutical Contract Research Organizations

Clinical Trial Recruitment in Respiratory Diseases- Most Clinical Trial Activity Focused on Asthma and COPD

Published: Nov-2011 Report Code: GBIHC158MR Report Format: Electronic PDF

Description

Inquire Before Buying

GBI Research’s report, “Clinical Trial Recruitment in Respiratory Diseases- Most Clinical Trial Activity Focused on Asthma and COPD”, provides an in-depth analysis of patient recruitment scenario for major indications under respiratory diseases. The report analyzes the number of clinical trials conducted for major indications. The report provides information about the total number of clinical trials conducted by phase, geography, major sponsors and the number of clinical trials conducted per year. Analysis of the total number of patients recruited for major indications is also carried out. The report analyzes the total number of patients recruited by phase of clinical trial, geography and major sponsors. Analysis of the average number of patients recruited per trial per year for various indications is also completed. Clinical trials are conducted to find novel therapies for respiratory diseases. The cost and time for conducting clinical trials for respiratory diseases is higher than other diseases. This is due to costly and time consuming testing methods. Patients are required to be tested for a longer duration leading to an increase in the total time required for drug effectiveness than seen in other diseases. Changing environmental conditions along with increases in tobacco smoking, air pollution and urbanization has lead to an increase in the prevalence of respiratory diseases. Asthma, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis (CF) and Pulmonary Arterial Hypertension (PAH) are few of the major respiratory diseases for which an increased number of clinical trials are conducted in order to determine the most effective treatment. In accordance to World Health Organization (WHO), the most common chronic disease among children is asthma. Asthma affects nearly 235 million people in the world. COPD was the cause of 5% of the total deaths in 2005. Tobacco smoking is the leading cause of COPD and in 2030. COPD will be the third leading cause of death. In light if this it becomes more important to find remedies for chronic respiratory diseases. CF is one of the most prevalent life-shortening diseases. It is a genetic disease which affects multiple organs. It is important to recruit the right type and number of patients to check the efficacy and efficiency of drugs. Efficient patient recruitment leads to a decrease in the time and cost associated with patient recruitment. At present, the rate of new drug approvals is declining with every passing year. Pharmaceutical companies are under intense pressure to reduce the time required for drug development. There are many barriers to participation for the patients as well as the investigators who enroll patients into the trials. Advances in the diagnosis and treatment of respiratory diseases are leading to a greater interest of pharmaceutical companies in sponsoring research into respiratory diseases.

Scope

Insight on Clinical Trials conducted for major indications of respiratory diseases such as asthma, COPD, CF, PAH or Pulmonary Hypertension (PH) for the period 2000–2010.
The status of patient recruitment by geographical region, sponsor company, year and stage of development.
Analysis on the average number of patients recruited per trial for major indications per year.
Analysis on the average number of patients recruited per trial for major indications by stage of development.
The prevalence population in India, China and Brazil for all major indications from 2010-2017.

Reasons to Buy

Identify and understand the status of clinical trials conducted for major respiratory indications from 2000-2010.
Build understanding of patient recruitment status by geography, sponsor company, year and stage of development.
Identify the prevalence population for the major indications till 2017.
Identify the average number of patients recruited by stage of development and across years for all major indications.
Identify the indication in which the maximum number of trials is conducted and and to which the maximum number of patients are recruited.

License Details

Single User License:

$3,500.00

Site License:

$7,000.00

Global License:

$10,500.00

Search Help
To run a quick Search on GBI Research site, enter the keywords for which you wish to search. By default, quick search will return documents which have at least any one of the words you have queried (an automatic "Or" search).

Detailed Functionality
• Higher relevance will be given to those documents where your search terms appear a greater number of times. Avoid using words such "and" or "or".

Phrase Searches
• You can search for a phrase by typing the keywords in quotation marks (""). For example, typing "Global Energy Efficient Lighting" will only return documents that contain this exact phrase.

Or Queries
• By default, search returns documents that include any of your search terms. There is no need to include or between terms. The order in which the terms are typed will affect the search results.

And Queries
• Adding and between two search terms means the search will return documents including both terms, whether they are listed together or not.


	Electronic PDF copy delivered via email. Report can be used by individual purchaser only.


	Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.


	Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

HomeIndustry ReportsPharmaceuticals and Healthcare Pharmaceutical Contract Research Organizations

Clinical Trial Recruitment in Respiratory Diseases- Most Clinical Trial Activity Focused on Asthma and COPD

Scope

Reasons to Buy

License Details

Home
Industry Reports
Pharmaceuticals and Healthcare

Pharmaceutical Contract Research Organizations